Physician profile
Ashlee Ann Eichenlaub
NPI 1376083857
$4,884.28
in general payments reported to CMS, 2019-2025
30 companies · $1,152 in 2025
The $1,152 reported for 2025 was more than what 89% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $900 · 2022: $467 · 2023: $1,787 · 2024: $579 · 2025: $1,152.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,518.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,517.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,191.77 | 2021-2025 | Xifaxan, Trulance, Uceris |
| Abbvie INC. | $843.08 | 2021-2025 | |
| Janssen Biotech, INC. | $381.86 | 2021-2025 | Stelara, Tremfya, Simponi |
| Takeda Pharmaceuticals U.S.A., INC. | $330.05 | 2021-2025 | Entyvio |
| Regeneron Healthcare Solutions, INC. | $258.69 | 2022-2024 | Dupixent |
| Pfizer INC. | $255.46 | 2021-2025 | |
| Ardelyx, INC. | $216.55 | 2025 | Ibsrela |
| Gilead Sciences, INC. | $199.38 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $192.11 | 2021-2023 | Dificid |
| Ironwood Pharmaceuticals, INC | $149.32 | 2021-2024 | Linzess |
| Genzyme Corporation | $130.71 | 2023-2024 | |
| Madrigal Pharmaceuticals | $95.79 | 2024-2025 | Rezdiffra, Resmetirom |
| Ferring Pharmaceuticals INC. | $79.90 | 2023 | Rebyota |
| Qol Medical, LLC | $76.45 | 2023-2024 | Sucraid, Sucraid |
| Aimmune Therapeutics, INC. | $75.88 | 2024-2025 | Zenpep |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $68.96 | 2023 | Wegovy |
| Braintree Laboratories, INC. | $38.49 | 2021 | |
| Kci USA, INC. | $36.82 | 2023 | Prevena |
| Intercept Pharmaceuticals, INC. | $35.61 | 2021-2024 | |
| Evoke Pharma, INC. | $34.03 | 2025 | |
| Phathom Pharmaceuticals, INC. | $31.33 | 2024 | Voquezna |
| Celltrion USA INC. | $30.74 | 2025 | Vegzelma |
| Daiichi Sankyo INC. | $23.15 | 2022 | |
| Nestle Healthcare Nutrition INC. | $20.64 | 2021 | |
| Redhill Biopharma INC. | $20.32 | 2021 | |
| Organon LLC | $15.45 | 2023 | Hadlima |
| Fresenius Kabi USA, LLC | $14.15 | 2023 | Idacio |
| Celgene Corporation | $13.91 | 2021 | |
| Phadia US INC. | $13.50 | 2021 | |
| Vivus LLC | $10.18 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashlee Eichenlaub listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.